Passage of irinotecan and its active metabolite, SN‐38, into human milk
Summary What is known and objective We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan to assess the potential risks when women treated with irinotecan nurse their infants. Case summary Human milk was collected for 6 days start...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2016-10, Vol.41 (5), p.579-582 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 582 |
|---|---|
| container_issue | 5 |
| container_start_page | 579 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 41 |
| creator | Nakagawa, J. Terui, K. Hosoi, K. Ueno, K. Yokoyama, Y. Hayakari, M. |
| description | Summary
What is known and objective
We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan to assess the potential risks when women treated with irinotecan nurse their infants.
Case summary
Human milk was collected for 6 days starting on the day after irinotecan was administered. The levels of irinotecan and SN‐38 in human milk were measured using liquid chromatography–mass spectrometry. Irinotecan was detected on Days 2 and 3 but not after Day 4. A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.
What is new and conclusion
Intravenously administered CPT‐11 continues to pass into human milk over a prolonged period in the form of its active metabolite, SN‐38. The relationship between administration of CPT‐11 and SN‐38 exposure and toxicity is still not well defined, so patients should avoid nursing their infants while they are being treated with CPT‐11.
A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk. |
| doi_str_mv | 10.1111/jcpt.12428 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819135869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4155620641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4228-98bb53e174838f807f243a706769645c93ad4b562c1d555c34a2525b4cf53fff3</originalsourceid><addsrcrecordid>eNp90LtOwzAYBWALgWgpLDwAssSCUFN8jZ0RVVyKKqhEmSPHscEllxInoG48As_Ik5CSwsDAv_zLp6OjA8AhRiPc3tlCL-sRJozILdDHNOQBERhtgz4iYRQwQUQP7Hm_QAiFgtBd0COCCUFQ2AeTmfJePRpYWugqV5S10aqAqkihqz1UunavBuamVkmZudoM4f3t5_sHlUPoirqET03e8txlz_tgx6rMm4PNH4CHy4v5-DqY3l1NxufTQDNCZBDJJOHUYMEklVYiYQmjSrTNwihkXEdUpSzhIdE45ZxryhThhCdMW06ttXQATrrcZVW-NMbXce68NlmmClM2PsYSR5hyGUYtPf5DF2VTFW27taKYi4iQVp12Slel95Wx8bJyuapWMUbxeuB4PXD8PXCLjzaRTZKb9Jf-LNoC3IE3l5nVP1HxzXg270K_AFOCg4s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1813157922</pqid></control><display><type>article</type><title>Passage of irinotecan and its active metabolite, SN‐38, into human milk</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nakagawa, J. ; Terui, K. ; Hosoi, K. ; Ueno, K. ; Yokoyama, Y. ; Hayakari, M.</creator><creatorcontrib>Nakagawa, J. ; Terui, K. ; Hosoi, K. ; Ueno, K. ; Yokoyama, Y. ; Hayakari, M.</creatorcontrib><description>Summary
What is known and objective
We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan to assess the potential risks when women treated with irinotecan nurse their infants.
Case summary
Human milk was collected for 6 days starting on the day after irinotecan was administered. The levels of irinotecan and SN‐38 in human milk were measured using liquid chromatography–mass spectrometry. Irinotecan was detected on Days 2 and 3 but not after Day 4. A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.
What is new and conclusion
Intravenously administered CPT‐11 continues to pass into human milk over a prolonged period in the form of its active metabolite, SN‐38. The relationship between administration of CPT‐11 and SN‐38 exposure and toxicity is still not well defined, so patients should avoid nursing their infants while they are being treated with CPT‐11.
A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.12428</identifier><identifier>PMID: 27477206</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Adult ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Camptothecin - metabolism ; Female ; human milk ; Humans ; infant ; irinotecan ; lactation ; Milk, Human - metabolism ; SN‐38</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2016-10, Vol.41 (5), p.579-582</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2016 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4228-98bb53e174838f807f243a706769645c93ad4b562c1d555c34a2525b4cf53fff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.12428$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.12428$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27477206$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakagawa, J.</creatorcontrib><creatorcontrib>Terui, K.</creatorcontrib><creatorcontrib>Hosoi, K.</creatorcontrib><creatorcontrib>Ueno, K.</creatorcontrib><creatorcontrib>Yokoyama, Y.</creatorcontrib><creatorcontrib>Hayakari, M.</creatorcontrib><title>Passage of irinotecan and its active metabolite, SN‐38, into human milk</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>Summary
What is known and objective
We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan to assess the potential risks when women treated with irinotecan nurse their infants.
Case summary
Human milk was collected for 6 days starting on the day after irinotecan was administered. The levels of irinotecan and SN‐38 in human milk were measured using liquid chromatography–mass spectrometry. Irinotecan was detected on Days 2 and 3 but not after Day 4. A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.
What is new and conclusion
Intravenously administered CPT‐11 continues to pass into human milk over a prolonged period in the form of its active metabolite, SN‐38. The relationship between administration of CPT‐11 and SN‐38 exposure and toxicity is still not well defined, so patients should avoid nursing their infants while they are being treated with CPT‐11.
A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.</description><subject>Adult</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - metabolism</subject><subject>Female</subject><subject>human milk</subject><subject>Humans</subject><subject>infant</subject><subject>irinotecan</subject><subject>lactation</subject><subject>Milk, Human - metabolism</subject><subject>SN‐38</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90LtOwzAYBWALgWgpLDwAssSCUFN8jZ0RVVyKKqhEmSPHscEllxInoG48As_Ik5CSwsDAv_zLp6OjA8AhRiPc3tlCL-sRJozILdDHNOQBERhtgz4iYRQwQUQP7Hm_QAiFgtBd0COCCUFQ2AeTmfJePRpYWugqV5S10aqAqkihqz1UunavBuamVkmZudoM4f3t5_sHlUPoirqET03e8txlz_tgx6rMm4PNH4CHy4v5-DqY3l1NxufTQDNCZBDJJOHUYMEklVYiYQmjSrTNwihkXEdUpSzhIdE45ZxryhThhCdMW06ttXQATrrcZVW-NMbXce68NlmmClM2PsYSR5hyGUYtPf5DF2VTFW27taKYi4iQVp12Slel95Wx8bJyuapWMUbxeuB4PXD8PXCLjzaRTZKb9Jf-LNoC3IE3l5nVP1HxzXg270K_AFOCg4s</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Nakagawa, J.</creator><creator>Terui, K.</creator><creator>Hosoi, K.</creator><creator>Ueno, K.</creator><creator>Yokoyama, Y.</creator><creator>Hayakari, M.</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope></search><sort><creationdate>201610</creationdate><title>Passage of irinotecan and its active metabolite, SN‐38, into human milk</title><author>Nakagawa, J. ; Terui, K. ; Hosoi, K. ; Ueno, K. ; Yokoyama, Y. ; Hayakari, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4228-98bb53e174838f807f243a706769645c93ad4b562c1d555c34a2525b4cf53fff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - metabolism</topic><topic>Female</topic><topic>human milk</topic><topic>Humans</topic><topic>infant</topic><topic>irinotecan</topic><topic>lactation</topic><topic>Milk, Human - metabolism</topic><topic>SN‐38</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakagawa, J.</creatorcontrib><creatorcontrib>Terui, K.</creatorcontrib><creatorcontrib>Hosoi, K.</creatorcontrib><creatorcontrib>Ueno, K.</creatorcontrib><creatorcontrib>Yokoyama, Y.</creatorcontrib><creatorcontrib>Hayakari, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakagawa, J.</au><au>Terui, K.</au><au>Hosoi, K.</au><au>Ueno, K.</au><au>Yokoyama, Y.</au><au>Hayakari, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Passage of irinotecan and its active metabolite, SN‐38, into human milk</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2016-10</date><risdate>2016</risdate><volume>41</volume><issue>5</issue><spage>579</spage><epage>582</epage><pages>579-582</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>Summary
What is known and objective
We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan to assess the potential risks when women treated with irinotecan nurse their infants.
Case summary
Human milk was collected for 6 days starting on the day after irinotecan was administered. The levels of irinotecan and SN‐38 in human milk were measured using liquid chromatography–mass spectrometry. Irinotecan was detected on Days 2 and 3 but not after Day 4. A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.
What is new and conclusion
Intravenously administered CPT‐11 continues to pass into human milk over a prolonged period in the form of its active metabolite, SN‐38. The relationship between administration of CPT‐11 and SN‐38 exposure and toxicity is still not well defined, so patients should avoid nursing their infants while they are being treated with CPT‐11.
A strong signal indicating the presence of SN‐38 was detected on Day 2 and the signal was readily detected until Day 7, indicating that SN‐38 remained in human milk.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>27477206</pmid><doi>10.1111/jcpt.12428</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2016-10, Vol.41 (5), p.579-582 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1819135869 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - metabolism Female human milk Humans infant irinotecan lactation Milk, Human - metabolism SN‐38 |
| title | Passage of irinotecan and its active metabolite, SN‐38, into human milk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A32%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Passage%20of%20irinotecan%20and%20its%20active%20metabolite,%20SN%E2%80%9038,%20into%20human%20milk&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Nakagawa,%20J.&rft.date=2016-10&rft.volume=41&rft.issue=5&rft.spage=579&rft.epage=582&rft.pages=579-582&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1111/jcpt.12428&rft_dat=%3Cproquest_cross%3E4155620641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1813157922&rft_id=info:pmid/27477206&rfr_iscdi=true |